Related Experiment Video
Updated: Aug 15, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[Long-term prognosis after surgery for pathological stage III lung cancer]
K Togashi1, M Saito, H Shinohara
1Department of Thoracic Surgery, Nagaoka Red Cross Hospital, Nagaoka, Japan.
Objective:
We studied for the purpose of revealing the long-term prognosis of the surgical treatment for pathological stage III lung cancer.
Method:
Two hundred fifty-four patients with pathological stage III disease who underwent surgical procedures in our hospital from 1981 to 2000 were investigated retrospectively.
Results:
The 5- and 10-year survival rates of 144 patients with stage IIIA disease were 35 and 25%, while those of 110 patients with IIIB disease were 30 and 16%. The 5- and 10-year survival rates were 40 and 27% for 52 patients with T1N2 disease, 33 and 23% for 70 patients with T2N2 disease, 34 and 0% for 9 patients with T3N1 disease, and 33 and 26% for 13 patients with T3N2 disease, respectively. In the patients with IIIB disease, the 5- and 10-year survival rates of 56 patients only with pml were 47 and 26%, those of the other patients were 9 and 0%. There is significant difference among them (p < 0.0001). In 54 patients with IIIB disease in addition to pm1, the 5-year survival rates of 19 patients with exploration only and the other patients were 7 and 14%, respectively. There were no 10-year survivors in both groups.
Conclusion:
The long-term prognosis of pathological stage III disease was still not satisfactory. Therefore, we should make efforts to get a sufficient informed-consent before the surgery for the patients with stage III disease.